Cite

HARVARD Citation

    Fu, W. et al. (2020). An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19. EClinicalMedicine. p. . [Online]. 
  
Back to record